Evidence based therapeutic apheresis in autoimmune and other hemolytic anemias

Current Opinion in Hematology

Volumn 14, Issue 6, 2007, Pages 647-654

  McLeod, Bruce C ^a,b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

Autoimmune hemolytic anemia; Plasma exchange; Red cell exchange; Sickle cell disease; Therapeutic apheresis; Thrombotic thrombocytopenic purpura

Indexed keywords

ANTITHROMBOCYTIC AGENT; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; PREDNISONE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

APHERESIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; CLINICAL FEATURE; CLINICAL TRIAL; ENZYME ASSAY; ERYTHROCYTE; EVIDENCE BASED MEDICINE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IRON OVERLOAD; NAUSEA AND VOMITING; PHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PUBLICATION; REVIEW; SICKLE CELL ANEMIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANEMIA, HEMOLYTIC; AUTOIMMUNE DISEASES; BLOOD COMPONENT REMOVAL; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 34848857389     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282c8ca66     Document Type: Review

References (61)

1. McLeod BC. An approach to evidence based therapeutic apheresis. J Clin Apheresis 2002; 17:124-132.
2. Szczepiorkowski ZM, Shaz BH, Bandarenko N, Winters JL. The new approach to assignment of ASFA categories-Introduction to the fourth special issue: Clinical applications of therapeutic apheresis. J Clin Apheresis 2007; 22:96-105. This presents a revised, updated, evidence-based approach to assessing the value and practicality of therapeutic apheresis for a given indication.
3. Petz LD. Treatment of autoimmune hemolytic anemias. Cur Opin Hematol 2001; 8:411-416.
4. McLeod B, Strauss RG, Ciavarella D, et al. Clinical applications of therapeutic apheresis; hematological disorders and cancer. J Clin Apheresis 1993; 8:211-230.
5. Szczepiorkowski ZM, Bandarenko N, Kim HC, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the apheresis applications committee of the American Society for Apheresis. J Clin Apheresis 2007; 22:106-175. Revised, updated discussions of individual diseases treated by therapeutic apheresis are presented. A 'fact sheet' format is used that presents a one-page summary of rationale, clinical and technical information for each disease along with an assessment of the quality of the evidence for benefit.
6. Buti S, Ricco M, Chiesa MD, et al. Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report. Anticancer Drugs 2007; 18:297-300. A patient who developed AHA during chemotherapy improved after treatment that included prednisone and TPE.
7. Wilson ML, Menjivar E, Kalapatapu V, et al. Mycoplasma pneumoniae associated with hemolytic anemia, cold agglutinins, and recurrent arterial thrombosis. South Med J 2007; 100:215-217. A patient with arterial thromboses in the context of postmycoplasma CAD improved after TPE was added to the treatment regimen.
8. Roy-Burman A, Glader BE. Resolution of severe Donath-Landsteiner autoimmune hemolytic anemia temporally associated with institution of plasmapheresis. Crit Care Med 2002; 30:931-934.
9. Valentini RP, Imam A, Warrier I, et al. Sirolimus rescue for tacrolimus-associated posttransplant autoimmune hemolytic anemia. Pediatr Transplant 2006; 10:358-361. Posttransplant CAD did not respond to TPE but resolved after a change in antirejection drugs.
10. Olcay L, Koc A. Autoimmune hemolytic anemia preceding T-ALL in a five-yearold girl. Pediatr Hematol Oncol 2005; 22:207-213.
11. Galor A, O'Brien T. Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndrome. Int J Hematol 2003; 78:335-336.
12. Ruivard M, Tournilhac O, Montel S, et al. Plasma exchanges do not increase red blood cell transfusion efficiency in severe autoimmune hemolytic anemia: a retrospective case-control study. J Clin Apheresis 2006; 21:202-206. Five AHA patients underwent TPE before some RBC transfusions. Their posttransfusion per-unit hemoglobin increments were compared with those of four nonrandomly chosen AHA patients who did not get TPE. Per-unit hemoglobin increments were not improved by TPE.
13. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966; 45:139-159.
14. Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 1977; 50:413-417.
15. Okuno T, Kosova L. Plasmapheresis for thrombotic thrombocytopenic purpura. Transfusion 1979; 19:342-344.
16. Taft EG. Thrombotic thrombocytopenic purpura and the dose of plasma exchange. Blood 1979; 54:842-849.
17. Myers TJ, Wakem CJ, Ball ED, Tremont SJ. Thrombotic thrombocytopenic purpura: combined treatment with plasmapheresis and antiplatelet agents. Ann Int Med 1980; 92:149-155.
18. McLeod B, Wu K, Knospe W. Plasmapheresis in thrombotic thrombocytopenic purpura. Arch Int Med 1980; 140:1059-1060.
19. Breckenridge RL, Solberg LA, Pineda AA, et al. Treatment of thrombotic thrombocytopenic purpura with plasma exchange, antiplatelet agents, corticosteroid, and plasma infusion: Mayo Clinic experience. J Clin Apheresis 1982; 1:6-13.
20. Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977; 297:1386-1389.
21. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354:1927-1935. A respected clinical hematologist presents the prevalent standard of care that most patients with otherwise unexplained thrombocytopenia and schistocytic anemia should receive urgent, daily TPE regardless of whether the clinical picture suggests TTP or HUS and regardless of ADAMTS13 levels; 80-90% survival is said to be expected. The mechanism of action of TPE is not elucidated.
22. Mayer SA, Aledort LM. Thrombotic microangiopathy: differential diagnosis, pathophysiology and therapeutic strategies. Mt Sinai J Med 2005; 72:166-175.
23. Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987; 32:292-308.
24. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome; clinical experience in 108 patients. N Engl J Med 1991; 325:398-403.
25. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325:393-397.
26. Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89:3097-3103.
27. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578-1584.
28. Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339:1585-1594.
29. Furlan M, Lämmle B. Haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura: new insights into underlying biochemical mechanisms. Nephrol Dial Transplant 2000; 15:1112-1114.
30. Veyradier A, Obert B, Houllier A, et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98:1765-1772.
31. Kremer Hovinga JA, Studt JD, Alberio L, Lämmle B. von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol 2004; 41:75-82.
32. Moake JL. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol 2004; 41:4-14.
33. Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 2005; 31:681-690.
34. Sarode R, McFarland JG, Flomenberg N, et al. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1995; 16:271-275.
35. McMinn JR Jr, Thomas IA, Terrell DR, et al. Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a study of 78 additional patients. Transfusion 2003; 43:415-416.
36. Peyvandi F, Ferrari S, Lavoretano S, et al. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Brit J Haematol 2004; 127:433-439.
37. Veseley SK, George JN, Lämmle B, et al. ADAMTS-13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102:60-68.
38. Veyradier A, Girma JP. Assays of ADAMTS-13 activity. Semin Hematol 2004; 41:41-47.
39. Kremer Hovinga JA, Mottini M, Lämmle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006; 4:1146-1148. This provides a concise description of a fluorescent resonance energy transfer assay using a synthetic peptide substrate to measure ADAMTS13 activity. The assay seems relatively quick and convenient, and its results showed reasonable concordance with those from five other assays in 30 patient samples.
40. Studt J-D, Böhm M, Budde U, et al. Measurement of von Willebrand factorcleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost 2003; 1:1882-1887.
41. Tripodi A, Chantarangkul V, Böhm M, et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004; 2:1601-1609.
42. Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005; 3:1710-1716.
43. Auton M, Cruz MA, Moake J. Conformational stability and domain unfolding of the Von Willebrand factor A domains. J Mol Biol 2007; 366:986-1000. This is a rigorous biochemical study of the stepwise conformational changes that occur in the several A domains of the vWF molecule as it transitions from the folded state to the string-like configuration in which it is susceptible to cleavage by ADAMTS13.
44. Dong JF, Moake JL, Bernardo A, et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003; 278:29633-29639.
45. Lopez JA, Dong JF. Shear stress and the role of high molecular weight von Willebrand factor multimers in thrombus formation. Blood Coagul Fibrinolysis 2005; 16 (Suppl 1):S11-S16.
46. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100:4033-4039.
47. Shenkman B. Role of ADAMTS-13 in platelet adhesion in flow: methods for diagnosis of thrombotic thrombocytopenic purpura. Pathophysol Haemost Thromb 2006; 35:98-102. This presents a brief account of ADAMTS13 assays including one devised by the author that utilizes shear stresses in an Impact-R device to unfold vWF.
48. Shelat SG, Smith P, Al J, Zheng XL. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 2006; 4:1707-1717. This study used several standard antigen-binding assays (e.g., immunoprecipitation, Western blot) as well as inhibition of ADAMTS13 enzymatic activity to detect antibodies to ADAMTS13. Noninhibitory antibodies found in some participants did not seem to accelerate clearance of ADAMTS13 from the circulation, whereas inhibitory antibodies appeared more likely to also increase clearance.
49. Scheiflinger F, Knobl P, Trattner B, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003; 102:3241-3243.
50. Roy V, Rizvi MA, Vesely SK, George JN. Thombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001; 27:641-646.
51. Raife T, Atkinson B, Montgomery R, et al. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004; 44:146-150.
52. Zakarija A, Bandarenko N, Kwaan H, et al. Risk factors for thrombotic thrombocytopenic purpura: results of the surveillance, epidemiology, and risk factors for TTP (SERF-TTP) group [abstract]. J Clin Apheresis 2007; 22:51-52.
53. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995; 126:896-899.
54. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339:5-11.
55. Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 2005; 80:70-74.
56. Division of Blood Disease and Resources. Management and therapy of sickle cell disease. 4th ed. http://www.nhlbi.nih.gov/health/prof/blood/sickle/ sc_mngt.pdf. Bethesda: National Heart, Lung, and Blood Institute National Heart, Lung, and Blood Institute; 2002. NIH Publication No. 02-2117.
57. Kwiatkowski JL, Cohen AR. Iron chelaton therapy in sickle-cell disease and other transfusion-dependent anemias. Hematol Oncol Clin North Am 2004; 18:1355-1377.
58. Kim HC, Dugan NP, Silber JH, et al. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood 1994; 83:1136-1142.
59. Singer ST, Quirolo K, Nishi K, et al. Erythrocytapheresis for chronically tranfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apheresis 1999; 14:122-125.
60. Vichinsky E, Onyekwere O, Porter J. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Brit J Haematol 2006; 136:501-508. One hundred and thirty-two SCD patients receiving deferasirox orally for 1 year were compared to 63 patients receiving deferoximine by continuous subcutaneous infusion. Patients with an elevated baseline creatinine were excluded. Similar reductions in liver iron content were seen in the two groups. Abdominal symptoms including nausea, vomiting diarrhea and pain were more common (20-28%) with deferasirox but were described as transient.
61. Voskaridou E, Douskou M, Terpos E, et al. Deferiprone as an oral iron chelator in sickle cell disease. Ann Hematol 2005; 84:434-440.